SLU-PP-332
Neutral, BioHarmony verdict
BioHarmony score 4.7 out of 10
SLU-PP-332 is a synthetic pan-ERR agonist developed in the Thomas Burris lab. Billon et al. 2023 showed increased mouse treadmill endurance after 8 days of injection, but no human trial, human pharmacokinetic study, or validated human dose exists.
Read full reportWhat is SLU-PP-332?
SLU-PP-332 is a synthetic exercise-mimetic research compound designed to activate the estrogen-related receptor family: ERR alpha, ERR beta, and ERR gamma. ERRs are orphan nuclear receptors that work with PGC-1 alpha to regulate mitochondrial biogenesis, fatty acid oxidation, oxidative muscle-fiber programs, and energy metabolism. In plain English, SLU-PP-332 tries to flip part of the same transcriptional switch endurance training flips.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
How it is thought to work
Activates estrogen-related receptor alpha, beta, and gamma, which partner with PGC-1 alpha to regulate mitochondrial biogenesis, fatty acid oxidation, oxidative muscle-fiber programs, and hepatic lipid handling.
Safety watch-outs
- Severe agitation or insomnia
- New muscle pain or weakness
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for SLU-PP-332 yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (4)
Attributed viewpoints, separate from primary research.
- Why Longevity Protocols Fail: Peptides, Stacks & the Science of Precision Alex Kikel,
- My Top Peptide Stack for Mental Clarity & Muscle Repair Alex Kikel,
- New Study On SLU-PP-332 Just Released Hunter Williams,
- SLU-PP-332 Dosage Per Day: How Much and When to Take It Jay Campbell,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
Published studies describe SLU-PP-332 as a synthetic small-molecule pan-ERR agonist with exercise-mimetic effects in mouse models. Human safety and effectiveness have not been established.
Primary sources
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome PubMed / Journal of Pharmacology and Experimental Therapeutics,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.